• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因内交联剂鉴定哺乳动物细胞中膜蛋白 PD-L1 的调控因子。

Genetically incorporated crosslinkers identify regulators of membrane protein PD-L1 in mammalian cells.

机构信息

Division of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu 610041, China.

Division of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu 610041, China; Collaborative Innovation Center of Biotherapy, West China Hospital of Sichuan University, Chengdu 610041, China.

出版信息

Cell Chem Biol. 2023 Nov 16;30(11):1488-1497.e5. doi: 10.1016/j.chembiol.2023.07.004. Epub 2023 Aug 3.

DOI:10.1016/j.chembiol.2023.07.004
PMID:37541256
Abstract

Profiling membrane proteins' interacting networks is crucial for understanding their regulatory mechanisms and functional characteristics, but it remains a challenging task. Here, by combining genetic incorporation of crosslinkers, tandem denatured purification, and proteomics, we added interaction partners for PD-L1, a cancer cell surface protein that inhibits T cell activity. The site-specifically incorporated crosslinker mediates the covalent capture of interactions under physiological conditions and enabled the PD-L1 complexes to withstand the harsh extraction conditions of membrane proteins. Subsequent experiments led to the identification of potential PD-L1 interaction candidates and verified membrane-associated progesterone receptor component 1 as a novel PD-L1 interaction partner in mammalian cells. Importantly, we demonstrated that PGRMC1 positively regulates PD-L1 expression by regulating GSK3β-mediated PD-L1 degradation in cancer cells. Furthermore, PGRMC1 knockdown results in dramatically enhanced T cell-mediated cytotoxicity in cancer cells. In conclusion, our study elucidated the interactome of PD-L1 and uncovered a new player in the PD-L1 regulation mechanism.

摘要

解析膜蛋白相互作用网络对于理解其调控机制和功能特征至关重要,但这仍然是一项具有挑战性的任务。在这里,我们结合了交联剂的遗传掺入、串联变性纯化和蛋白质组学,为 PD-L1 添加了相互作用伙伴,PD-L1 是一种癌细胞表面蛋白,可抑制 T 细胞活性。特异性掺入的交联剂介导了生理条件下相互作用的共价捕获,并使 PD-L1 复合物能够耐受膜蛋白的苛刻提取条件。随后的实验鉴定出了潜在的 PD-L1 相互作用候选物,并验证了膜相关孕激素受体成分 1 是哺乳动物细胞中 PD-L1 的一个新的相互作用伙伴。重要的是,我们证明了 PGRMC1 通过调节 GSK3β 介导的 PD-L1 降解来正向调节 PD-L1 的表达。此外,PGRMC1 的敲低导致癌细胞中 T 细胞介导的细胞毒性显著增强。总之,我们的研究阐明了 PD-L1 的相互作用组,并揭示了 PD-L1 调节机制中的一个新角色。

相似文献

1
Genetically incorporated crosslinkers identify regulators of membrane protein PD-L1 in mammalian cells.基因内交联剂鉴定哺乳动物细胞中膜蛋白 PD-L1 的调控因子。
Cell Chem Biol. 2023 Nov 16;30(11):1488-1497.e5. doi: 10.1016/j.chembiol.2023.07.004. Epub 2023 Aug 3.
2
Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells.PD-L1 细胞质结构域同源二聚化调控其在活细胞中的复合糖基化。
Commun Biol. 2022 Aug 30;5(1):887. doi: 10.1038/s42003-022-03845-4.
3
PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.程序性死亡配体 1(B7-H1)与 RNA 外切体竞争以调节 DNA 损伤反应,并且可以作为靶点以增敏放疗或化疗。
Mol Cell. 2019 Jun 20;74(6):1215-1226.e4. doi: 10.1016/j.molcel.2019.04.005. Epub 2019 Apr 30.
4
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.
5
N-methyladenosine-modified circIGF2BP3 inhibits CD8 T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.N6-甲基腺苷修饰的环状 IGF2BP3 通过促进非小细胞肺癌中 PD-L1 的去泛素化来抑制 CD8 T 细胞反应,从而促进肿瘤免疫逃逸。
Mol Cancer. 2021 Aug 20;20(1):105. doi: 10.1186/s12943-021-01398-4.
6
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.使用叶酸功能化聚亚乙基亚胺靶向递送 PD-L1 siRNA 的卵巢癌免疫治疗:增强 T 细胞杀伤的策略。
Adv Healthc Mater. 2015 Jun 3;4(8):1180-9. doi: 10.1002/adhm.201500089. Epub 2015 Apr 11.
7
Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.度伐鲁单抗联合免疫调节药物(IMiD)克服了由于 IMiD 诱导骨髓瘤细胞 PD-L1 上调导致的抗肿瘤反应抑制。
Mol Cancer Ther. 2021 Jul;20(7):1283-1294. doi: 10.1158/1535-7163.MCT-20-0246. Epub 2021 Apr 20.
8
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.去泛素化酶 USP22 调节人类癌细胞中的 PD-L1 降解。
Cell Commun Signal. 2020 Jul 14;18(1):112. doi: 10.1186/s12964-020-00612-y.
9
PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.程序性死亡受体配体1(PD-L1)通过激活WIP和β-连环蛋白信号通路促进肿瘤生长和进展,并预示肺癌预后不良。
Cell Death Dis. 2020 Jul 6;11(7):506. doi: 10.1038/s41419-020-2701-z.
10
FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.FAT4 过表达通过调节β-连环蛋白/STT3/PD-L1 轴促进宫颈癌中的抗肿瘤免疫。
J Exp Clin Cancer Res. 2023 Sep 1;42(1):222. doi: 10.1186/s13046-023-02758-2.

引用本文的文献

1
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine.B细胞淋巴瘤免疫治疗的新视野:从免疫检查点到精准医学
Neoplasia. 2025 Jun 30;67:101206. doi: 10.1016/j.neo.2025.101206.
2
In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy.原位编辑肿瘤细胞膜诱导 PD-L1 膜蛋白聚集和捕获,增强癌症免疫治疗。
Nat Commun. 2024 Nov 9;15(1):9723. doi: 10.1038/s41467-024-54081-9.
3
Genetic Code Expansion for Mechanistic Studies in Ion Channels: An (Un)natural Union of Chemistry and Biology.
遗传密码扩展在离子通道的机理研究中的应用:化学与生物学的(非)天然结合。
Chem Rev. 2024 Oct 23;124(20):11523-11543. doi: 10.1021/acs.chemrev.4c00306. Epub 2024 Aug 29.
4
Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy.针对 PD-L1 胞质结构域及其调控通路以增强癌症免疫治疗。
J Mol Cell Biol. 2024 Apr 10;15(11). doi: 10.1093/jmcb/mjad070.